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The Chinese herb Dichroa febrifuga has traditionally
treated malaria-associated fever. Its active compo-
nent febrifugine (FF) andderivatives such as halofugi-
none (HF) are potent anti-malarials. Here, we show
that FF-based derivatives arrest parasite growth by
direct interaction with and inhibition of the protein
translation enzyme prolyl-tRNA synthetase (PRS).
Dual administration of inhibitors that target different
tRNA synthetases suggests high utility of these
drug targets.We reveal the ternary complex structure
of PRS-HF and adenosine 50-(b,g-imido)triphosphate
where the latter facilitates HF integration into the PRS
active site. Structural analyses also highlight spaces
within the PRS architecture for HF derivatization
of its quinazolinone, but not piperidine, moiety. We
also show a remarkable ability of HF to kill the related
human parasite Toxoplasma gondii, suggesting
wider HF efficacy against parasitic PRSs. Hence,
our cell-, enzyme-, and structure-based data on
FF-based inhibitors strengthen the case for their
inclusion in anti-malarial and anti-toxoplasmosis
drug development efforts.
INTRODUCTION
Plasmodium parasites are the causative agents of malaria, with
an estimated 0.5 million deaths annually. Due to increasing inci-
dence of chloroquine and artemisinin resistance, the World
Health Organization (WHO) recommends combination chemo-
therapy for malaria. There is also increased emphasis on estab-
lishing drug pipelines that can generate new anti-malarials
by using modern and traditional lead compounds. The ancient
Chinese herb Dichroa febrifuga has been used to treat malaria
for many centuries (Koepfli et al., 1947). The active component
of this herb is a quinazolinone-type alkaloid called febrifugineStructure 23(FF) (Coatney et al., 1950). However, owing to its gastrointestinal
toxicity, it was derivatized to yield less toxic compounds (Hewitt
et al., 1952). Among this new class of derivatives, halofuginone
(HF) showed reduced cellular toxicity (Ryley and Betts, 1973).
HF is currently used as a coccidiostat against Eimeria (Ryley
and Wilson, 1975) and Cryptosporidium (Linder et al., 2007) in-
fections. Studies on HF promise utility against scleroderma, can-
cer, and fibrotic disease (Elkin et al., 1999; Halevy et al., 1996;
McGaha et al., 2002; Pines and Nagler, 1998; Pines et al.,
2003). Recently, the molecular target of HF in humans was iden-
tified as the prolyl-tRNA synthetase (PRS) enzyme (Keller et al.,
2012; Son et al., 2013; Zhou et al., 2013), amember of the amino-
acyl-tRNA synthetase (aaRS) family. The latter are ancient en-
zymes responsible for genetic code translation (Ibba and Soll,
2000), which attach amino acids onto cognate tRNAs for protein
translation in an aminoacylation reaction. We and others have
studied critical cellular processes such as nucleosome assembly
and lipid import in themalaria parasites (Chandra et al., 2005; Gill
et al., 2009; Navadgi et al., 2006; Sharma and Sharma, 2011;
Sharma et al., 2008). However, lack of experimentally verified
‘‘hit’’ compounds has hampered the discovery of potent malaria
parasite inhibitors against these protein targets (Chandra et al.,
2005; Gill et al., 2009; Navadgi et al., 2006; Sharma and Sharma,
2011; Sharma et al., 2008). Encouragingly, several groups have
been investigating the structure-function attributes of aaRSs
within malaria parasites (Bhatt et al., 2009, 2011; Istvan et al.,
2011; Jackson et al., 2011; Jain et al., 2014; Khan et al., 2011,
2013a, 2013b, 2014; Koh et al., 2012; Pham et al., 2014). Target-
ing parasitic aaRSs can provide an additional drug component in
current multidrug anti-malarial therapy (Bhatt et al., 2009, 2011;
Hoepfner et al., 2012; Istvan et al., 2011; Jackson et al., 2011;
Jain et al., 2014; Khan et al., 2011, 2013a, 2013b, 2014; Koh
et al., 2012; Pham et al., 2014).
Structural studies have previously suggested that in the case
of human PRS, HF mimics the enzyme substrates L-Pro and
adenine 76 (A76) of tRNA and then binds into their ‘‘active site
pockets’’ simultaneously, but with the assistance of ATP (Keller
et al., 2012; Son et al., 2013; Zhou et al., 2013). These findings
generated intense excitement about the molecular target of HF
in Plasmodium parasites. We then showed direct and strong, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 819
HF binding to the Plasmodium falciparum PRS (PfPRS), thus es-
tablishing the cellular target of this drug in malaria parasites (Jain
et al., 2014). In the past two decades, many synthetic derivatives
of FF and HF have been reported with potent anti-malarial
activity (Kikuchi et al., 2006, 2014), and it is very likely that these
compounds work by targeting the malaria protein translation
machinery by inhibition of the PRS.
Here, we investigate racemicmixtures of quinazolinone-based
compounds, namely halofuginone (HF), febrifugine (FF), 6-fluoro
febrifugine (6F-FF), and tetrahydro quinazolinone febrifugine
(Th-FF), using crystallography, cell- and enzyme-based drug
interaction assays. We show their differential utility against ma-
laria parasites, and present a structural basis for their interaction
with the PfPRS enzyme. The atomic structure of the ternary com-
plex of PfPRS-halofuginone (PfPRS-HF) in complex with adeno-
sine 50-(b,g-imido)triphosphate (AMPPNP) reveals intricacies of
drug binding, and suggests chemical spaces available for further
drug derivatization. Our dual drug inhibition study on malaria
parasites using HF and cladosporin (a P. falciparum lysyl-tRNA
synthetase [PfKRS] inhibitor) (Hoepfner et al., 2012; Khan et al.,
2013a, 2014) validates the Plasmodium tRNA synthetase family
as valuable new targets for drug development. There is high con-
servation in HF chelating residues in many pathogen PRSs;
based on this we tested HF against Toxoplasma parasites. We
show very high potency inhibition of Toxoplasma parasite growth
by HF, thus establishing these quinazolinone-based compounds
as general anti-apicomplexan compounds. Our comprehensive
analyses provide a platform for focusing on PRS as a new target
for the development of novel malaria and toxoplasmosis inter-
vention strategies.
RESULTS
Evaluation of PRS-Drug Binding and Inhibition
We performed cell- and enzyme-based inhibition assays to
address drug-like properties of the four quinazolinone-based
compounds HF, FF, 6F-FF, and Th-FF (Figure 1; Figure S1).
The 3D7 strain of P. falciparum was tested for effects of these
inhibitors after 48 hr of incubation in concentration ranges of
0.01 nM to 10 mM for each. The drugs HF, FF, 6F-FF, and Th-
FF killed malaria parasites in the very first cycle of erythrocytic
development, suggesting that the likely target for these inhibitors
was cytoplasmic PfPRS and not apicoplastic PfPRS (Hoen
et al., 2013). For each of the four tested inhibitors (Figure 1A),
dose-dependent inhibition followed sigmoidal curves with 50%
effective concentration (EC50) in the subnanomolar ranges of
1–190 nM (Figure 1B), consistent with earlier reports (Derbyshire
et al., 2012; Geary et al., 1983; Kikuchi et al., 2006, 2014). The
EC50 values of HF were increased to 5 and 20 nM, respectively,
in the presence of 53 and 203 L-Pro (RPMI media supple-
mented with higher L-Pro concentration) in the culture media,
in line with a competitive inhibition mode of binding in context
of the PRS natural substrate L-proline (Figure 1B). To investigate
whether HF, FF, 6F-FF, and Th-FF were specific for PfPRS, and
would thereby abrogate protein synthesis by inhibiting the
enzyme directly, we performed aminoacylation assays in the
presence of these drugs (Figure 1C). Our recombinant PfPRS
efficiently catalyzed aminoacylation reactions (Figure 1D), which
were quantitatively measured by the amount of pyrophosphate820 Structure 23, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rightsreleased and then estimated using standard curves. For enzyme
inhibition studies, concentration ranges of 0.01 nM to 10 mM
were used for the four compounds, and inhibitions were
assessed in dose-dependent fashion. These revealed 50%
inhibitory concentration (IC50) values of 9, 24, 13, and 352 nM,
respectively, for HF, FF, 6F-FF, and Th-FF (Figure 1D). We also
investigated the binding of HF, FF, 6F-FF, and Th-FF with PfPRS
in thermal shift assays (Figure 1E). The profile of PfPRS alone
(apo) gave amelting temperature (Tm) of50C at which the ratio
of unfolded to folded protein was 1 (Figure 1E). Addition of 6F-FF,
Th-FF, and FF individually to PfPRS did not alter the PfPRS ther-
mal profile substantially (small changes of 0.5C to 1.5C in Tm
were observed). This was in contrast to the PfPRS-apo interac-
tion with HF, which produced a significant rise of 15C in enzyme
Tm (Figure 1E). However, the addition of ATP analog AMPPNP
along with Th-FF, FF, 6F-FF, and HF inhibitors resulted in a sub-
stantial Tm shift of 30C to 40C, indicating specificity, higher
affinity, and greater stability of PfPRS-inhibitor-AMPPNP com-
plexes (Figure 1E). To estimate the relative binding affinities of
HF and AMPPNP for PfPRS, we also performed concentration-
dependent thermal shift assays. Binding constants (Kd) were
estimated by examining the systematic effect of increasing HF
concentration on PfPRS stability (Figure 1F). A concentration
range of 0.01 nM to 10 mM was used for HF, while AMPPNP
was used at a constant concentration of 1 mM (Figure 1F). The
Kd of PRS-HF was estimated as 300 nM, and interestingly
the PfPRS-HF binding affinity increased 30-fold in the pres-
ence of AMPPNP to9 nM (Figure 1F). In addition, we performed
isothermal titration calorimetry (ITC) experiments (Figure S1) to
determine the Kd of HF for PRS-AMPPNP complex. These
data reveal value of 19 nM, similar to those obtained from
our thermal shift assay (TSA) experiments (9 nM). These data
together reveal that HF binding to PfPRS is promoted in the
presence of AMPPNP, consistent with earlier data on human
PRS (Zhou et al., 2013). The drug binding assays (TSA and
ITC) and aminoacylation inhibition data together suggest strong
and specific interaction between PfPRS and compounds HF, FF,
6F-FF, and Th-FF.
Structure of PfPRS-HF-AMPPNP Complex and
Comparison with Human PRS
To dissect the structural basis of inhibitor selectivity by PfPRS
and the apparent increase in drug affinity in presence of
AMPPNP, we attempted co-crystallization of PfPRS with HF,
FF, 6F-FF, and Th-FF. We succeeded in growing crystals of
PfPRS in complex with HF and AMPPNP. The crystals were in
themonoclinic space group (P21)where the asymmetric unit con-
tainedonedimer of PfPRS-HF-AMPPNPwith a solvent content of
56%. The structure was solved at 2.3 A˚ resolution bymolecular
replacement method using PfPRS-apo (PDB code 4TWA) as a
search model (Figure 2A). The organization and overall fold of
PfPRS ternary complex is similar to that in our earlier report of
PfPRS-apo structure (root-mean-square deviation [RMSD] is
0.6 A˚ for 475 Ca atoms) (Jain et al., 2014). PfPRS shares 54%
identity with human PRS and yielded an RMSD of 1.3 A˚ for 470
Ca atoms, with limited deviations in AB binding and Z domains
only (Figure 2B). In our PfPRS-HF-AMPPNP structure, we
observed clear electron densities for the two protomers except
for tRNA recognition residues 327–334 and motif 1 residuesreserved
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Figure 1. Binding and Inhibition of PfPRS
(A) Chemical structures of halofuginone (HF),
febrifugine (FF), 6-fluoro febrifugine (6F-FF),
tetrahydro quinazolinone febrifugine (Th-FF), and
the ATP analog (adenosine 50-(b,g-imido)triphos-
phate, AMPPNP). The color used for the com-
pound names corresponds to the curve color used
for the rest of the graphs.
(B) Parasite growth inhibition assays in the pres-
ence of HF, FF, 6F-FF, and Th-FF. The experi-
ments were performed at seven concentrations
ranging from 0.1 nM to 10 mM. The EC50 values are
the mean ± SD (n = 3) nM and are as follows: 1 ±
0.3 for HF; 2 ± 0.5 for 6F-FF; 4 ± 0.6 for FF; 192 ±
4.3 for Th-FF; 24 ± 2.1 for chloroquine; 5 ± 1.1 for
HF with 53 L-Pro; and 21 ± 1.0 for HF with 203
L-Pro.
(C) Aminoacylation assays in the presence of HF,
FF, 6F-FF, and Th-FF. These experiments were
performed at seven concentrations ranging from
0.1 nM to 10 mM. The IC50 values are the mean ±
SD (n = 3) nM and are as follows: 9 ± 0.6 for HF
(red); 13 ± 1.5 for 6F-FF (blue); 24 ± 1.7 for FF
(yellow); and 352 ± 17.2 for Th-FF (green).
(D) Aminoacylation activity assays using recom-
binant PfPRS. Data represent dependence of
PO4
2 formation versus time. Two moles of PO4
2
are formed for every mole of tRNAPro that is acyl-
ated. Aminoacylation curves with (blue line) and
without (red line) added PfPRS and tRNAPro. Serial
dilutions of PO4
2 in reaction buffer were incu-
bated with malachite green solution and the
absorbance was measured at 621 nm.
(E) Thermal shift assays with HF, FF, 6F-FF, and
Th-FF inhibitors. The inhibitors bind PfPRS in the
absence of AMPPNP but interact more strongly in
its presence.
(F) Dose-dependent thermal melting curves of
PfPRS in the presence of HFwith AMPPNP. Values
shown are the mean (n = 3). The binding affinity of
HF alone and HF with AMPPNP, calculated using
themelting profile (Matulis et al., 2005), was9 nM
and 300 nM, respectively. See also Figure S1.697–707; however, a larger overall B factor was observed for
molecule B (49 A˚2) when compared with molecule A (39 A˚2) (Fig-
ure 2B). Superposition of PfPRS catalytic domains on Homo sa-
piens PRS (HsPRS) (PDB 4HVC) showed that the conformation
and location of bound AMPPNPs and HFs in each protomer are
identical (Figure 2B). The ligands HF and AMPPNP were found
in their respective pockets with well-defined electron densities
(Figure 2C). In both PfPRS and HsPRS, AMPPNP was located
in thecanonical ATPbindingpocket andwas stabilizedby several
hydrogen bonds, water molecules, and hydrophobic contacts
(Figure 2B). However, a significant deviation was observed for
the terminal phosphate group of AMPPNP in PfPRS when
compared with the ligand bound HsPRS (Figures 2D and 2E). In
PfPRS, the adenosine ring of AMPPNP stacks between Phe405
and Arg514, and the ribose moiety forms hydrogen bonds with
Gln475, Arg514, Thr478, and awatermolecule, while Arg390 sta-
bilizes phosphates, Lys384, Arg401, and water ensconced Mg2+
(Figures 3A and 3B). Furthermore, in both HsPRS and PfPRS, theStructure 23a-phosphate group of AMPPNP is proximal to HF and forms
hydrogen bonds with the hydroxyl group of HF piperidine ring
along with its keto group (Figure 3B). The extensive hydrophilic
and hydrophobic interactions position the AMPPNP in a bent
conformation in both HsPRS and PfPRS (Figures 3A and 3B).
However, the residue Thr478 forms a hydrogen bond with the
piperidine ring hydroxyl of HF in PfPRS but not in HsPRS (Fig-
ure 3A). From the electron density analysis of Thr478 (Figure 3A),
it is evident that its side chain adopts alternate conformations,
thereby permitting its hydroxyl group to bond hydrogen with
the hydroxypiperidine of HF. The refined occupancies of major
and minor conformations of Thr478 are 0.56/0.46 and 0.67/0.33
for molecules A and B, respectively. Thus, Thr478 makes
hydrogen bonds to both HF and AMPPNP via major and minor
conformations, respectively. The occupancies of bound ligands
HF/AMPPNP (0.96/0.91 and 0.92/0.88 for molecules A and
B, respectively) were also refined and indicate fully ligand
bound states. However, the equivalent residue Thr1240 in, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 821
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Figure 2. Crystal Structure of the PfPRS-HF-AMPPNP Ternary Complex
(A) PfPRS dimer in the asymmetric unit of PfKRS-HF-AMPPNP crystals is shown with bound HF (yellow) and AMPPNP (pink). Catalytic (C domain, residues 255–
532), anti-codon binding (AB domain, residues 533–655), C-terminal zinc binding like (Z domain, residues 656–746) domains aswell as protein termini aremarked.
(B) Superposition of PfPRS-HF-AMPPNP (blue) and HsPRS-HF-AMPPNP (green) structures. HF and AMPPNP, and Mg2+ and Zn2+ ions are shown as sticks and
spheres, respectively.
(C) A simulated annealing composite omit map generated to 2.3 A˚ resolution contoured at 1.2s showing the bound ligands HF (yellow), AMPPNP (pink), andMg2+
(green).
(D and E) Two views showing the tight binding of HF and AMPPNP, and the conformational deviation of three phosphate groups between human andPlasmodium
PRSs. The color codes are the same as in Figure 1B.HsPRS-HF-AMPPNP complex does not make contact with HF
(Zhou et al., 2013).
Although we used a racemic mixture of HF (commercial
source), it is evident from the structure of PfPRS-HF-AMPPNP
complex that the bound compound is the 2R,3S-(+) enantiomer
of HF (7-bromo-6-chloro-3-[3-[hydroxy-2-piperidinyl]-2-oxo-
propyl]-4-quinazolinone) (Figure 2C). In PfPRS, the N atom
of the HF piperidine ring forms hydrogen bonds with Thr359
and Glu361, and the quinazolinone ring is mainly stabilized by
hydrophobic interactions, particularly by hydrophobic stacking
contacts and interactions of AMPPNP phosphate groups. These
intimate interactions thus provide a direction to the binding pose
of HF (Figure 4A). Interestingly, water molecule interactions
around HF and AMPPNP are different between PfPRS and
HsPRS structures (Figure 3B). The bromine and chlorine atoms
of HF interact with hydrophobic residues and water molecules,
respectively (Figure 4C). The bromine links with the main-chain
carbonyl O atom of Phe335 and is completely surrounded by
hydrophobic stem of Glu338 and Val339, leaving no space for
further additive modifications. In contrast, the chloride hydrogen822 Structure 23, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rightsbonds with two waters and is mostly solvent exposed, thus
spatially potentiating additional modifications or derivatization
(Figure 4C). The HF piperidine ring, in contrast again, is fully sur-
rounded by the proline binding residues with no empty spaces
(Figure 4C). Hence, efforts at derivatization of FF via its haloge-
nated positions can focus around the chlorine position.
Active Site Conservation in Pathogen PRSs and
Targeting Dual aaRSs
The architectures of class II synthetase active sites have re-
mained largely conserved over the course of evolution. There-
fore, we considered whether HF could potentially kill related
human parasites such as Toxoplasma spp., among others (Fig-
ure 4D). Indeed, we found invariance in all critical HF binding res-
idues in PRSs from the human pathogens analyzed (Figure 4D).
We thus conjectured that HF may kill Toxoplasma parasites via
mechanisms similar to those described above. Propelled by
these observations, we assessed the effect of HF on the growth
of Toxoplasma gondii in human primary foreskin fibroblasts (Fig-
ure 5A). The compoundHF inhibited T. gondii intracellular growthreserved
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Figure 3. Structural Basis for AMPPNP-Dependent Inhibition of PfPRS by Halofuginone
(A) Important interactions between HF piperidine ring with a-phosphate atoms of AMPPNP and protein residues in PfPRS (left) and HsPRS (right) are shown. The
interactions are shown by dashed lines and the distances are marked. The inset mFo-DFc (3.5s level) and 2mFo-DFc (1.5s level) electron densities display the
alternative conformations of Thr478 in PfPRS. The color codes of the ligands and protein residues are the same as in Figure 2B. The Mg2+ ion (green) and water
molecules (red) are shown as spheres.
(B) The g-phosphate group of AMPPNP forms several hydrogen bonding interactions with protein residues, HF, and water molecules, and forms a coordination
bond with Mg2+.at exceedingly low nanomolar concentrations (EC50 0.94 nM;
Figure 5A). It is noteworthy that halofuginone was more effective
in inhibiting T. gondii growth in a 24 hr assay than the known
potent drug pyrimethamine (EC50 = 650 nM; Figure 5A), a com-
pound currently used clinically. Using high-content imaging
(HCI) assays, we monitored T. gondii invasion and growth over
a 24 hr period during which it was evident that HF killed Toxo-
plasma faster than the clinical drug pyrimethamine, displaying
its higher potency. While HF clearly stops endodyogeny at lowStructure 23concentrations (Figure 5B), it is able to partially prevent invasion
when parasites are pretreated with a higher concentration
(50 nM; Figure 5C). These data and insights are consistent with
the commercially validated utility of HF as a coccidiostat for
Eimeria and cryptosporidium infections (Linder et al., 2007; Ryley
and Wilson, 1975), from which we now predict that HF acts via
inhibition of PRS enzyme.
The blooming of the tRNA synthetase family as worthy drug
targets in the context of anti-apicomplexan drug discovery is, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 823
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Figure 4. Important HF Binding Pocket Residues
(A) Two views showing the important HF binding pocket residues within 5 A˚. Protein residues are shown in stick representations with a transparent overlay of the
corresponding Van der Waals surface.
(B) Temperature factor distribution around the active site of PfPRS and HsPRS structures from low (blue) to high (red).
(C) Views of the HF binding pocket. The halogen atoms of HF make interactions within the PRS active site pocket and fill the whole cavity. The hydroxypiperidine
ring and the Br site are enclosed in very tight spaces within the enzyme. An accessory pocket is observed near the HF chloride atom and the keto group of
4-quinazoline. Non-halogenated derivatives of FF or partially halogenated ones (such as 6F-FF) are most likely deficient in fully occupying active site cavities
within PfPRS.
(D) Multiple sequence alignment of likely HF binding site residues (blue) from various pathogenic PRSs: Plasmodium falciparum (Pf), Plasmodium vivax (Pv),
Cryptosporidium parvum (Cp), Eimeria tenella (Et), Leishmania major (Lm), Toxoplasma gondii (Tg), Trypanosoma brucei (Tb), Candida albicans (Ca), and
Aspergillus flavus (Af) along with Homo sapiens (Hs). The important secondary shell residues are colored red.highly encouraging. In malaria alone, lead development based
on the natural products cladosporin (CL, targets lysyl-tRNA syn-
thetase [KRS]) and FF / HF (target PRS) is ongoing. Hence, we
decided to test the effects of co-administration of CL and HF
on parasite growth. HF was used at 1 nM and CL at 48 nM so
as to cause 50% reduction in malaria parasite growth (Fig-
ure 6A). This level of growth inhibition (EC50) was used to
determine, using isobologram analysis, whether the interaction
between the two drugs exhibited a synergistic or additive anti-
malarial effect. The data indicated that the drug combination
was indeed additive in all ratios tested (Figure 6A).
DISCUSSION
The 36-member P. falciparum parasite tRNA synthetase family,
which together governs transmission of genetic information824 Structure 23, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rightsinto proteins, has been focus of intense research lately (Bhatt
et al., 2009, 2011; Istvan et al., 2011; Jackson et al., 2011; Jain
et al., 2014; Khan et al., 2011, 2013a, 2013b, 2014; Koh et al.,
2012; Pham et al., 2014). The recent discovery and validation
of cladosporin utility against multiple malaria parasitic stages,
and its specificity for PfKRS, has been a seminal contribution
in validating aaRSs as new drug targets (Hoepfner et al., 2012;
Khan et al., 2013a, 2014). Cladosporin is composed of a THP
ring (2,6-disubstituted tetrahydropyran) fused to an isocoumarin
moiety, and mimics ribose and adenine moieties of the natural
substrate ATP, resulting in a scaffold capable of competitive
inhibition (Hoepfner et al., 2012; Khan et al., 2013a, 2014). Clado-
sporin inhibits the malaria parasite with an EC50 of 48 nM;
however, its poor bioavailability (ADME [absorption, distribution,
metabolism, and excretion] properties) is a hurdle, and hence its
derivatization is under way.reserved
Figure 5. Effect of HF on T. gondii
(A) EC50 values against T. gondii RH tachyzoites
were plotted for the clinically relevant compound
pyrimethamine and for halofuginone.
(B) Numbers of parasites per vacuole (1, 2, 4, 8,
or 16) were counted 24 hr after DMSO (vehicle) or
halofuginone treatments.
(C) Parasite invasion was monitored following
DMSO (vehicle) or halofuginone treatments.Another natural product isolated from a Chinese herb, FF, and
its halogenated derivative, HF, have shown promising potency
as anti-malarials (Hewitt et al., 1952; Derbyshire et al., 2012)
and as a veterinary coccidiostat (Linder et al., 2007; Ryley and
Wilson, 1975). HF is being explored as therapy for scleroderma,
cancer, and fibrotic disease (Elkin et al., 1999; Halevy et al.,
1996; McGaha et al., 2002; Pines and Nagler, 1998; Pines
et al., 2003). HF is composed of a quinazolinone ring fused to hy-
droxypiperidine ring and these respectively mimic the natural
substrates adenine (30 tRNA A76) and L-proline, resulting in a
PRS dual-site inhibition with assistance from ATP (Son et al.,
2013; Zhou et al., 2013). Recently, we have shown direct binding
of HF to PfPRS (Jain et al., 2014).
Here, using assays for malaria parasite growth and enzyme in-
hibition, we demonstrate drug-like utilities of FF and its deriva-
tives (HF, 6F-FF, and Th-FF; Table 1). Intriguingly, the thermal
shift profiles indicated that all four compounds interacted with
PfPRS in the presence of AMPPNP. Among the four compounds
in the presence of AMPPNP, halogenated FF derivatives
conferred higher thermal stability than non-halogenated ones
(FF and Th-FF). Uniquely, of all four, only HF was able to confer
a 15C Tm shift with PfPRS alone. The measured binding affin-
ity of HFwith PfPRS in the presence of AMPPNP throughmelting
curve analysis (TSA) was 9 nM, consistent with the ITC data
(19 nM; Figure 1E; Figure S1). The observed inhibition values
for HF and 6F-FF (metabolically vulnerable aromatic protons
substituted with halogen atoms) suggest that additional halo-
gen(s) increases the potency and activity of FF derivatives.
We propose that derivatization of FF via its chlorine position
may be feasible from a structural perspective in search of lead
molecules.
The substrate binding pockets in PfPRS and HsPRS are highly
conserved (Son et al., 2013; Zhou et al., 2013). Our sequence
and structure-based exploration of related pathogen PRSs
reveals conservation in the HF interacting residues within PRSStructure 23, 819–829, May 5, 2015active sites. Hence, HF-like compounds
may be ofmuchwider utility in drug devel-
opment efforts that target pathogen
PRSs. These predictions are validated
by our data on HF-mediated killing of
Toxoplasma parasites. We also tested
whether dual anti-tRNA synthetase inhib-
itors can be useful in combination. For
this, we used KRS and PRS inhibitors
(cladosporin and HF) simultaneously on
P. falciparum parasites, revealing additive
inhibitory effects on growth. It is note-
worthy that the binding sites and mecha-nism of action of cladosporin and HF are different (Figure 6B). In
summary, our work substantiates and directs focus on exploita-
tion of HF-based leads for the generation of specific and effec-
tive therapeutics against human and animal pathogens.
EXPERIMENTAL PROCEDURES
P. falciparum Culture
P. falciparum 3D7 was cultured in O+ erythrocytes in RPMI 1640 (Invitrogen)
supplemented with 4.5 mg ml1 glucose (Sigma), 0.1 mM hypoxanthine (Invi-
trogen), 25 mg ml1 gentamicin (Invitrogen), and 0.5% AlbuMax-I (Invitrogen),
according to standard methods (Trager and Jensen, 2005). Parasites were
sorbitol treated in ring stages to maintain a synchronized culture as described
by Tonkin et al. (2004).
P. falciparum Growth Inhibition Assays
HFwas dissolved in DMSO (Sigma) while FF, 6F-FF, and Th-FF were dissolved
in double-distilled water. The 3D7 strain of P. falciparum was cultured in
96-well plates and synchronized at ring stages. At 1% parasitemia and 4%
hematocrit, HF, FF, 6F-FF, and Th-FF from 0.01 nM to 10 mM were incubated
for 48 hr with the parasite culture. Parasite growth was assayed by the SYBR
green I (Molecular Probes) DNA staining assay as described earlier (Smilkstein
et al., 2004). In brief, 100 ml of SYBR green dye in 13 concentration in
lysis buffer supplemented with 0.1% saponin was added to each well. After
45 min incubation at 37C, fluorescence was estimated using a multiwell plate
reader (Victor 3, Perkin Elmer) with excitation and emission wavelength bands
centered at 485 and 530 nm, respectively. Chloroquine was taken as a positive
control and all experiments were performed in triplicate. For competition ex-
periments with L-proline, this was added to the culture during the assays.
The EC50 values were obtained by plotting fluorescence values expressed in
terms of percentage inhibition of parasite growth at each inhibitor concentra-
tion. Analysis was done using non-linear regression analysis with GraphPad
Prism 5 software. All data are shown for three replicates as the mean ± SE.
Protein Purification and Thermal Shift Assays
PfPRS was produced in accordance with methods published (Jain et al.,
2014). TSAs for PfPRS in the presence of HF, FF, 6F-FF, and Th-FF were per-
formed as reported earlier (Jain et al., 2014). For dose-dependent TSA, PfPRS
was diluted in buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl, andª2015 Elsevier Ltd All rights reserved 825
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Figure 6. Drug Combination Study
(A) Isobologram demonstrating the additive action of CL
and HF on 3D7 parasites. HF at 1 nM and CL at 48 nMwere
added alone to the culture, which reduced the parasite
growth to 50% (red line). The experimental data points
show the ratios of drug combinations (red for drugs used
alone and blue for both drugs) that give 50% inhibition in
parasite growth.
(B) Summary of tRNA synthetase localizations and drug
targeting to date. HF is an ATP-dependent dual-site in-
hibitor of PRS as it occupies both the proline binding and
the 30 tRNAPro pocket. CL is known to interact with the ATP
binding residues of PfKRS. Using HF andCL in combination
will thus be targeting two different enzymes simultaneously,
increasing the potency of inhibition via abrogating protein
translation in the parasites. The upper figure shows the
localization data on 36 P. falciparum aaRSs within blood-
stage red blood cells (RBCs) in different parasite com-
partments. PRS and KRS are shown in ribbon diagrams
based on their crystal structures in complex with the drugs.
The cartoon represents data on class II synthetases that are
so far validated via the use of HF and CL.
826 Structure 23, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rights reserved
Table 1. Summary of the Inhibition and Tm Values of Tested Inhibitors in Plasmodium falciparum
S. No. Inhibitor
Enzyme Inhibition
IC50 (nM)
Parasite (3D7) Inhibition
EC50 (nM)
Change in Melting Temperature DTm (
C) Mammalian Cells
EC50 (nM)
Selectivity
IndexOnly Drug Drug with AMPPNP
1 HF 9 ± 0.6 1 ± 0.3 15 ± 0.6 40 ± 0.7 150 ± 9a 150
2 FF 24 ± 1.7 4 ± 0.6 1.5 ± 0.2 33 ± 0.5 450 ± 20b 118
3 6F-FF 13 ± 1.5 2 ± 0.5 0.5 ± 0.1 35 ± 0.5 205 ± 12b 108
4 Th-FF 352 ± 7.2 192 ± 4.3 1 ± 0.1 31 ± 0.4 190000 ± 1100c 934
aKeller et al., 2012.
bKikuchi et al., 2006.
cKikuchi et al., 2014.23 SYPRO orange dye (Life Technologies). HF (Sigma) at concentrations
ranging from 0.1 nM to 1 mM with and without AMPPNP (Sigma) at 1 mM
were added to PfPRS (3 mM) and incubated at room temperature for 10 min.
PfPRS-apo and with various drugs were heated from 25C to 99C at a rate
of 1C min1 and fluorescence signals were monitored by the StepOne Plus
quantitative real-time PCR system (Life Technologies). Each curve is an
average of three measurements, and data were analyzed using Thermal Shift
software (Life Technologies). Inhibitors and AMPPNP alone in assay buffers,
with no protein controls, were used, and flat lines were observed for these fluo-
rescence readings at all temperatures. Derivative Tm was used for analysis.
Binding constant calculations were done as reported earlier (Matulis et al.,
2005).
Crystallization
Highly pure protein was stored in 15 mM HEPES (pH 7.5), 200 mM NaCl, and
10mM b-mercaptoethanol at 193 K. Before crystallization, 3 mMHF and 5mM
AMPPNP were added to protein and incubated at 4 C for 10 min. Crystalliza-
tion was achieved using a vapor diffusion method in hanging drops. A TTP
Labtech Mosquito robot was employed to mix 100 nl of PfPRS-AMPPNP-HF
complex with 100 nl of well solutions from commercially available crystal
screens. Diffraction-quality crystals were obtained with the well solution
0.1 M Bis-Tris (pH 6.5), 2 % (v/v) Tacsimate (pH 5.0), and 12% (w/v) polyeth-
ylene glycol 3350.
Aminoacylation Assays
cDNA oligonucleotideswere purchased fromSigmawith one containing the T7
RNA polymerase promoter followed by gene encoding the tRNApro while the
other primer encoded the complementary strand with promoter and the
tRNA gene. These two oligos were mixed in equimolar ratios in an annealing
buffer (10 mM Tris [pH 8.0], 50 mM NaCl, and 0.5 mM EDTA), heated to
95C and then cooled slowly at room temperature. The annealed dsDNA
was used as template for in vitro transcription reaction to produce tRNApro,
performed using the Ambion Maxiscript T7 in vitro transcription kit. The enzy-
matic assays were done according to an earlier report (Cestari and Stuart,
2013) where the standard aminoacylation reaction ingredients were aminoacy-
lation buffer (30 mM HEPES [pH 7.4], 140 mM NaCl, 30 mM KCl, and 40 mM
MgCl2), 1 mM DTT, 200 mM ATP, 2 U/ml inorganic pyrophosphatase (Sigma-
Aldrich), 10 mM L-Pro (Sigma-Aldrich), 8 mM P. falciparum tRNApro, and
0.4 mM recombinant PRS. The aminoacylation reactions (55 ml total volume
each) were performed in clear, flat-bottomed, 96-well plates (Costar 96-well
standard microplates), and the reaction mixtures were incubated for 30 min
at 37C. Liberated inorganic phosphate was detected by addition of 15 ml of
malachite green solution (Baykov et al., 1988) and incubated for 30 min at
room temperature. Absorbance was measured at 621 nm using a Versa Max
microplate reader. Reactions without enzyme or without L-Pro were per-
formed as background controls, and data from reactions without L-Pro were
subtracted from the measurements. For time-course experiments, 10 mM
EDTA was added to the reaction mixture at different time points (0, 2, 5, 8,
10, 20, and 30 min) and mixed on ice to stop the reaction. For PRS inhibition,
a reaction solution containing PRS (0.4 mM)wasmixed with HF, FF, 6F-FF, and
Th-FF at 0.1 nM to 10 mM in a 50-ml volume and incubated for 20 min at 37C.
Reactions were stopped as described above. All data are shown for three
replicates as the mean ± SE.Structure 23Data Collection and Structure Determination
X-Ray diffraction datawere collected at 100 K usingCuKa radiation (l = 1.54 A˚)
on an MAR345 image-plate detector mounted on a Rigaku MicroMax-007
rotating-anode X-ray generator. A total of 300 images were collected with
10 min exposure and 1 oscillation per frame. The diffraction images were pro-
cessed and scaled with the HKL-2000 program suite. Structure was solved by
molecular replacement in Phaser (McCoy et al., 2007) using the PfPRS-apo
structure (Jain et al., 2014) (PDB code: 4TWA) as the template. There are two
PfPRS-HF-AMPPNP complexes in the asymmetric unit with a solvent content
of 56%. The model was initially refined using REFMAC5 (Murshudov et al.,
2011) and completed with phenix.refine in PHENIX (Adams et al., 2010).
X-Ray refinement restraint parameters were generated for HF molecule using
the Sketcher program in the CCP4 Suite (Winn et al., 2011). HF, AMPPNP,
and water molecules were added into the electron density maps using COOT
(Emsley and Cowtan, 2004). The quality of the final model and bound ligands
was verifiedusing composite simulated annealingomitmaps. Theoccupancies
of bound ligands and alternate conformations of protein residues were refined
and confirmed using omit maps. Final model quality was analyzed using
MolProbity (Chen et al., 2010), and the final model has 98% residues in favored
regionsand the remaining2%residues inallowed regionsof theRamachandran
plot. Statistics for data collection and structure refinement are given in Table 2.
All structural superimposition and preparation of figures was done using UCSF
Chimera (Pettersen et al., 2004) and PyMOL (http://www.pymol.org). The dimer
interface buried surface area, hydrogen bonds, and salt bridges were analyzed
usingPISA (Krissinel andHenrick, 2007). Atomiccoordinates andstructural fac-
tors have been deposited into the PDB with accession code 4YDQ.
T. gondii Growth Inhibition
Methods and procedures for this section are available in the Supplemental
Methods.
Analysis of Drug Cocktail on P. falciparum Growth
The isobologrammethodwas used to evaluate the effects of co-administration
of two tRNA synthetase inhibitors (HF and CL) as described previously (Loewe,
1953; Steel and Peckham, 1979). The concentrations of HF and CL required to
reduce parasite growth by 50% (EC50) were determined and plotted on the x
and y axes in a two-coordinate plot. A straight line connecting these two
50% growth points (for the two drugs) corresponds to the line of additivity.
Concentrations of HF and CL used in different combinations (x:y) were plotted.
All points above the additivity line suggest antagonism between drugs and
those below indicate synergism. In this case, experimental data points along
the line indicate additive effects between the two drugs.
ACCESSION NUMBERS
Coordinates and structure factors for PfPRS-HF-AMPPNP have been depos-
ited in the RCSB PDB under accession code 4YDQ.
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Table 2. Data Collection and Refinement Statistics
PfPRS- HF- AMPPNP
Data Collection
Space group P21
Cell dimensions
a, b, c (A˚) 81.0, 88.9, 86.3
a, b, g () 90, 96.7, 90
Resolution (A˚) 50.0–2.3 (2.34–2.3)
Rmerge (%) 0.090 (0.50)
I/s(I) 21.2 (2.8)
Completeness (%) 99.5 (95.0)
Redundancy 5.8 (5.1)
Refinement
Resolution 27.8–2.30 (2.36–2.30)
No. of reflections 51,322 (4,938)
Rwork/Rfree (%) 18.1/23.1
No. of atoms
Protein 7,686
Ligand/ions 110/2
Water 291
B factor (A˚2)
Protein 41.6
Ligand/ions 27.9/51.0
Water 37.0
RMSD
Bond length (A˚) 0.010
Bond angle () 1.275
Values in parentheses are for the highest-resolution shell.AUTHOR CONTRIBUTIONS
V.J. performed purification of the enzyme, biochemical assays, and crystal-
lization, and analyzed the data. V.J. and M.Y. collected X-ray data and deter-
mined the structure. B.T. and M.H. performed Toxoplasma-based assays.
Y.O. and H.K. synthesized the FF derivatives. A.S. designed the study and
participated in data analysis. All authors discussed the results and wrote
the manuscript.
ACKNOWLEDGMENTS
This research was supported by DBT, Government of India OSRP grant
PR6303 to A.S., and DBT grant PR3084 to A.S. and M.Y. V.J. is supported
by a DBT Senior Research Fellowship. A.S. is additionally supported by
the JC Bose fellowship. B.T. and M.A.H. are supported by the European
Research Council (ERC Consolidator grant no. 614880 Hosting TOXO to
M.A.H.).
Received: December 17, 2014
Revised: February 16, 2015
Accepted: February 22, 2015
Published: March 26, 2015
REFERENCES
Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N.,
Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010).
PHENIX: a comprehensive Python-based system for macromolecular struc-
ture solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.828 Structure 23, 819–829, May 5, 2015 ª2015 Elsevier Ltd All rightsBaykov, A.A., Evtushenko, O.A., and Avaeva, S.M. (1988). A malachite green
procedure for orthophosphate determination and its use in alkaline phospha-
tase-based enzyme immunoassay. Anal. Biochem. 171, 266–270.
Bhatt, T.K., Kapil, C., Khan, S., Jairajpuri, M.A., Sharma, V., Santoni, D.,
Silvestrini, F., Pizzi, E., and Sharma, A. (2009). A genomic glimpse of amino-
acyl-tRNA synthetases in malaria parasite Plasmodium falciparum. BMC
Genomics 10, 644.
Bhatt, T.K., Khan, S., Dwivedi, V.P., Banday, M.M., Sharma, A., Chandele, A.,
Camacho, N., Ribas de Pouplana, L., Wu, Y., Craig, A.G., et al. (2011).
Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory
responses. Nat. Commun. 2, 530.
Cestari, I., and Stuart, K. (2013). A spectrophotometric assay for quantitative
measurement of aminoacyl-tRNA synthetase activity. J. Biomol. Screen. 18,
490–497.
Chandra, B.R., Olivieri, A., Silvestrini, F., Alano, P., and Sharma, A. (2005).
Biochemical characterization of the two nucleosome assembly proteins from
Plasmodium falciparum. Mol. Biochem. Parasitol. 142, 237–247.
Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M.,
Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010).
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.
Coatney, G.R., Cooper, W.C., Culwell, W.B., White, W.C., and Imboden, C.A.,
Jr. (1950). Studies in human malaria. XXV. Trial of febrifugine, an alkaloid
obtained from Dichroa febrifuga Lour., against the Chesson strain of
Plasmodium vivax. J. Natl. Malar. Soc. 9, 183–186.
Derbyshire, E.R., Mazitschek, R., and Clardy, J. (2012). Characterization
of Plasmodium liver stage inhibition by halofuginone. ChemMedChem 7,
844–849.
Elkin, M., Ariel, I., Miao, H.Q., Nagler, A., Pines,M., de-Groot, N., Hochberg, A.,
and Vlodavsky, I. (1999). Inhibition of bladder carcinoma angiogenesis, stromal
support, and tumor growth by halofuginone. Cancer Res. 59, 4111–4118.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
Geary, T.G., Divo, A.A., and Jensen, J.B. (1983). An in vitro assay system for
the identification of potential antimalarial drugs. J. Parasitol. 69, 577–583.
Gill, J., Yogavel, M., Kumar, A., Belrhali, H., Jain, S.K., Rug, M., Brown, M.,
Maier, A.G., and Sharma, A. (2009). Crystal structure of malaria parasite nucle-
osome assembly protein: distinct modes of protein localization and histone
recognition. J. Biol. Chem. 284, 10076–10087.
Halevy, O., Nagler, A., Levi-Schaffer, F., Genina, O., and Pines, M. (1996).
Inhibition of collagen type I synthesis by skin fibroblasts of graft versus
host disease and scleroderma patients: effect of halofuginone. Biochemical
Pharmacol. 52, 1057–1063.
Hewitt, R.I., Wallace, W.S., Gill, E.R., and Williams, J.H. (1952). An antimalarial
alkaloid from Hydrangea. XIII. The effects of various synthetic quinazolones
against Plasmodium lophurae in ducks. Am. J. Trop. Med. Hyg. 1, 768–772.
Hoen, R., Novoa, E.M., Lopez, A., Camacho, N., Cubells, L., Vieira, P., Santos,
M., Marin-Garcia, P., Bautista, J.M., Cortes, A., et al. (2013). Selective
inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium
falciparum. ChemBioChem 14, 499–509.
Hoepfner, D., McNamara, C.W., Lim, C.S., Studer, C., Riedl, R., Aust, T.,
McCormack, S.L., Plouffe, D.M., Meister, S., Schuierer, S., et al. (2012).
Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA
synthetase by the fungal secondary metabolite cladosporin. Cell Host
Microbe 11, 654–663.
Ibba, M., and Soll, D. (2000). Aminoacyl-tRNA synthesis. Annu. Rev. Biochem.
69, 617–650.
Istvan, E.S., Dharia, N.V., Bopp, S.E., Gluzman, I., Winzeler, E.A., and
Goldberg, D.E. (2011). Validation of isoleucine utilization targets in
Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 108, 1627–1632.
Jackson, K.E., Habib, S., Frugier, M., Hoen, R., Khan, S., Pham, J.S., Ribas de
Pouplana, L., Royo, M., Santos, M.A., Sharma, A., et al. (2011). Protein trans-
lation in Plasmodium parasites. Trends Parasitol. 27, 467–476.reserved
Jain, V., Kikuchi, H., Oshima, Y., Sharma, A., and Yogavel, M. (2014). Structural
and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase.
J. Struct. Funct. Genomics 15, 181–190.
Keller, T.L., Zocco, D., Sundrud, M.S., Hendrick, M., Edenius, M., Yum, J.,
Kim, Y.J., Lee, H.K., Cortese, J.F., Wirth, D.F., et al. (2012). Halofuginone
and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem.
Biol. 8, 311–317.
Khan, S., Sharma, A., Jamwal, A., Sharma, V., Pole, A.K., Thakur, K.K., and
Sharma, A. (2011). Uneven spread of cis- and trans-editing aminoacyl-tRNA
synthetase domains within translational compartments of P. falciparum. Sci.
Rep. 1, 188.
Khan, S., Garg, A., Camacho, N., Van Rooyen, J., Kumar Pole, A., Belrhali, H.,
Ribas de Pouplana, L., Sharma, V., and Sharma, A. (2013a). Structural analysis
of malaria-parasite lysyl-tRNA synthetase provides a platform for drug devel-
opment. Acta Crystallogr. D Biol. Crystallogr. 69, 785–795.
Khan, S., Garg, A., Sharma, A., Camacho, N., Picchioni, D., Saint-Leger, A.,
Ribas de Pouplana, L., Yogavel, M., and Sharma, A. (2013b). An appended
domain results in an unusual architecture for malaria parasite tryptophanyl-
tRNA synthetase. PLoS One 8, e66224.
Khan, S., Sharma, A., Belrhali, H., Yogavel, M., and Sharma, A. (2014).
Structural basis of malaria parasite lysyl-tRNA synthetase inhibition by clado-
sporin. J. Struct. Funct. Genomics 15, 63–71.
Kikuchi, H., Yamamoto, K., Horoiwa, S., Hirai, S., Kasahara, R., Hariguchi, N.,
Matsumoto, M., and Oshima, Y. (2006). Exploration of a new type of antima-
larial compounds based on febrifugine. J. Med. Chem. 49, 4698–4706.
Kikuchi, H., Horoiwa, S., Kasahara, R., Hariguchi, N., Matsumoto, M., and
Oshima, Y. (2014). Synthesis of febrifugine derivatives and development of
an effective and safe tetrahydroquinazoline-type antimalarial. Eur. J. Med.
Chem. 76, 10–19.
Koepfli, J.B., Mead, J.F., and Brockman, J.A., Jr. (1947). An alkaloid with high
antimalarial activity from Dichroa febrifuga. J. Am. Chem. Soc. 69, 1837.
Koh, C.Y., Kim, J.E., Shibata, S., Ranade, R.M., Yu, M., Liu, J., Gillespie, J.R.,
Buckner, F.S., Verlinde, C.L., Fan, E., et al. (2012). Distinct states of methionyl-
tRNA synthetase indicate inhibitor binding by conformational selection.
Structure 20, 1681–1691.
Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies
from crystalline state. J. Mol. Biol. 372, 774–797.
Linder, M.R., Heckeroth, A.R., Najdrowski, M., Daugschies, A., Schollmeyer,
D., and Miculka, C. (2007). (2R,3S)-(+)- and (2S,3R)-(-)-halofuginone lactate:
synthesis, absolute configuration, and activity against Cryptosporidium par-
vum. Bioorg. Med. Chem. Lett. 17, 4140–4143.
Loewe, S. (1953). The problem of synergism and antagonism of combined
drugs. Arzneimittelforschung 3, 285–290.
Matulis, D., Kranz, J.K., Salemme, F.R., and Todd, M.J. (2005).
Thermodynamic stability of carbonic anhydrase: measurements of binding
affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258–5266.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C.,
and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr.
40, 658–674.
McGaha, T., Kodera, T., Phelps, R., Spiera, H., Pines, M., and Bona, C. (2002).
Effect of halofuginone on the development of tight skin (TSK) syndrome.
Autoimmunity 35, 277–282.Structure 23Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A.,
Nicholls, R.A., Winn, M.D., Long, F., and Vagin, A.A. (2011). REFMAC5
for the refinement of macromolecular crystal structures. Acta Crystallogr. D
Biol. Crystallogr. 67, 355–367.
Navadgi, V.M., Chandra, B.R., Mishra, P.C., and Sharma, A. (2006). The two
Plasmodium falciparum nucleosome assembly proteins play distinct roles in
histone transport and chromatin assembly. J. Biol. Chem. 281, 16978–16984.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M.,
Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera—a visualization system
for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.
Pham, J.S., Dawson, K.L., Jackson, K.E., Lim, E.E., Pasaje, C.F., Turner, K.E.,
and Ralph, S.A. (2014). Aminoacyl-tRNA synthetases as drug targets in
eukaryotic parasites. Int. J. Parasitol. Drugs Drug Resist. 4, 1–13.
Pines, M., and Nagler, A. (1998). Halofuginone: a novel antifibrotic therapy.
Gen. Pharmacol. 30, 445–450.
Pines, M., Snyder, D., Yarkoni, S., and Nagler, A. (2003). Halofuginone to treat
fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood
Marrow Transplant. 9, 417–425.
Ryley, J.F., and Betts, M.J. (1973). Chemotherapy of chicken coccidiosis. Adv.
Pharmacol. Chemother. 11, 221–293.
Ryley, J.F., and Wilson, R.G. (1975). Laboratory studies with some recent
anticoccidials. Parasitology 70, 203–222.
Sharma, A., and Sharma, A. (2011). Fatty acid induced remodeling within the
human liver fatty acid-binding protein. J. Biol. Chem. 286, 31924–31928.
Sharma, A., Yogavel, M., Akhouri, R.R., Gill, J., and Sharma, A. (2008). Crystal
structure of soluble domain of malaria sporozoite protein UIS3 in complex with
lipid. J. Biol. Chem. 283, 24077–24088.
Smilkstein,M., Sriwilaijaroen, N., Kelly, J.X.,Wilairat, P., andRiscoe,M. (2004).
Simple and inexpensive fluorescence-based technique for high-throughput
antimalarial drug screening. Antimicrob. Agents Chemother. 48, 1803–1806.
Son, J., Lee, E.H., Park, M., Kim, J.H., Kim, J., Kim, S., Jeon, Y.H., and Hwang,
K.Y. (2013). Conformational changes in human prolyl-tRNA synthetase upon
binding of the substrates proline and ATP and the inhibitor halofuginone.
Acta Crystallogr. D Biol. Crystallogr. 69, 2136–2145.
Steel, G.G., and Peckham, M.J. (1979). Exploitable mechanisms in combined
radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol.
Biol. Phys. 5, 85–91.
Tonkin, C.J., van Dooren, G.G., Spurck, T.P., Struck, N.S., Good, R.T.,
Handman, E., Cowman, A.F., and McFadden, G.I. (2004). Localization of or-
ganellar proteins in Plasmodium falciparum using a novel set of transfection
vectors and a new immunofluorescence fixation method. Mol. Biochem.
Parasitol. 137, 13–21.
Trager, W., and Jensen, J.B. (2005). Human malaria parasites in continuous
culture. J. Parasitol. 91, 484–486.
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans,
P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011).
Overview of the CCP4 suite and current developments. Acta Crystallogr. D
Biol. Crystallogr. 67, 235–242.
Zhou, H., Sun, L., Yang, X.L., and Schimmel, P. (2013). ATP-directed capture
of bioactive herbal-based medicine on human tRNA synthetase. Nature 494,
121–124., 819–829, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 829
